INFLARX N.V. EO 0,12 WKN: A2H7A5 ISIN: NL0012661870 Kürzel: IFRX Forum: Aktien Thema: Hauptdiskussion

Invitation to InflaRx Virtual R&D event on Vilobelimab for the Treatment of Hidradenitis Suppurativa We are pleased to invite you to our virtual R&D event to provide insight on the development of vilobelimab in Hidradenitis Suppurativa (HS), including details on the Phase III study design and primary endpoint. The event will take place virtually on Thursday, February 3, 2022 from 8:30 AM EST/2:30 PM CET to 10:30 AM EST/4:30 PM CET. To participate in the event, please pre-register here and you will receive a dedicated link and dial-in details to easily and quickly access the call. In addition to InflaRx executives, Christopher Sayed, MD, Associate Professor of Dermatology, University of North Carolina School of Medicine, Chapel Hill, NC, will speak at the event. Dr. Sayed is a dermatology specialist with extensive experience in the treatment of HS. He will discuss the disease and its impact on patients, including the need for new treatment options to fight the disease and improve patient quality of life. Further Information on the event can be found on the Company’s website in the Investors – Events & Presentations section. If you have questions, please contact: InflaRx N.V.

News diesen Monat noch

🎁🎁🎁

Alles unter 4 € ist Geschenk

Was für ein Rebound

Wow

Live Übertragung

J.p Morgan Conferenz 17.15

Kommen News ?

Läuft

Schönes Plus heute

🙈

Da hängen ja ne Menge Faktoren von ab. Zulassung covid: produziert inflarx selbst? Vertreibt inflarx selbst? Wie viele Bestellungen erhalten wir von Regierungen? Ich würde sagen, der Kurs schwankt bei Zulassung zwischen 20 und 100 Euro. Denn wenn es noch off Label Anwendungen gibt, dann knallt es gewaltig im Gebälk.(Wallstreet)

Die longs werden es nicht bereuen. Niels hat sein ganzes Herzblut da reingesteckt. Ich freu mich wenn endlich was passiert. Schon 2 Jahre dabei :)

Viele große Investoren und Fonds werden die Conferenz verfolgen bin gespannt

40th Annual J.P. Morgan Healthcare Conference: Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, will give a corporate presentation on Thursday, January 13th at 11:15 am EST (5:15 pm CET) followed by a 20-minute Q&A. A live audio webcast and replay of the presentation will be provided on the InflaRx website in the Investors - Events & Presentations section.